Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 6,111 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 6,111 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.10, for a total value of $960,038.10. Following the transaction, the chief executive officer now owns 179,071 shares in the company, valued at $28,132,054.10. The trade was a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, May 1st, Steven Leonard Chapman sold 6,980 shares of Natera stock. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00.
• On Monday, April 28th, Steven Leonard Chapman sold 6,203 shares of Natera stock. The stock was sold at an average price of $152.18, for a total value of $943,972.54.
• On Monday, April 21st, Steven Leonard Chapman sold 1,664 shares of Natera stock. The stock was sold at an average price of $145.55, for a total value of $242,195.20.
• On Monday, March 31st, Steven Leonard Chapman sold 9,563 shares of Natera stock. The shares were sold at an average price of $138.41, for a total transaction of $1,323,614.83.
• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total transaction of $978,693.06.

Natera Stock Up 4.4%

Shares of NTRA opened at $167.22 on Thursday. The firm has a market cap of $22.83 billion, a P/E ratio of -95.01 and a beta of 1.79. The stock has a 50 day simple moving average of $150.83 and a two-hundred day simple moving average of $158.58. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1 year low of $92.14 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s revenue for the quarter was up 36.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on NTRA. Wall Street Zen downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Robert W. Baird lifted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Royal Bank of Canada started coverage on shares of Natera in a report on Thursday, March 13th. They set an “outperform” rating and a $251.00 price objective on the stock. Finally, BTIG Research reissued a “buy” rating on shares of Natera in a report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $184.63.

Institutional Trading of Natera

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of Natera during the first quarter valued at approximately $8,992,000. Geneos Wealth Management Inc. raised its holdings in shares of Natera by 142.9% during the first quarter. Geneos Wealth Management Inc. now owns 1,098 shares of the medical research company’s stock valued at $155,000 after acquiring an additional 646 shares in the last quarter. IFM Investors Pty Ltd bought a new position in shares of Natera during the first quarter valued at approximately $3,498,000. Intech Investment Management LLC raised its holdings in shares of Natera by 591.4% during the first quarter. Intech Investment Management LLC now owns 85,369 shares of the medical research company’s stock valued at $12,072,000 after acquiring an additional 73,021 shares in the last quarter. Finally, Focus Partners Wealth raised its holdings in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.